The ferocity of China’s biopharmaceutical investment boom this year – fuelled by record-breaking licensing of commercial rights to global giants after a three-year slump – may have surprised casual observers. But according to Helen Chen, one of the most respected analysts and advisers in China’s life sciences space, the supercharged sector’s real renaissance came two years earlier. In December 2022, US drug maker MSD agreed to license global (excluding China) rights to develop and commercialise…
You must log in or # to comment.